Standard Chartered Appoints Manus Costello as New CFO Amid Leadership Reshuffle 
Analog Devices Nears $1.5B Acquisition of AI Chip Firm Empower Semiconductor 
Honda Shares Jump as Automaker Forecasts Profit Recovery Despite Historic Loss 
Amazon Faces Class-Action Lawsuit Over Trump Tariff Price Hikes 
Samsung, Union Edge Closer to Deal as Strike Threat Looms 
US-China Trade Talks Sideline Chip Export Controls as Nvidia China Sales Draw Attention 
Warren Buffett and Stephen Curry Charity Dinner Auction Raises $27 Million for Nonprofits 
Elliott Targets Bio-Rad as Shares Continue to Struggle 
Samsung Faces Major Strike Threat as Union Restarts Pay Talks 
TrumpRx Expands Discount Drug Access With 600 Generic Medications 
Standard Chartered Targets Higher Profitability With Major Workforce Cuts 
Sonova Beats Profit Forecasts Despite Cochlear Implant Weakness 
Samsung Union Talks Enter Final Stage as Strike Threat Looms 
FTC Antitrust Probe Targets Arm Holdings Over Chip Licensing Practices 
Anthropic Nears $30 Billion Funding Round at $900 Billion Valuation 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
SEATTLE, Sept. 20, 2016 -- Cascadian Therapeutics (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that Julie Eastland, Chief Financial Officer, will present a corporate overview at the Ladenburg Thalmann 2016 Healthcare Conference. The presentation will take place at 8:30am EDT on Tuesday, September 27, 2016 in New York City.
A live and archived webcast of the presentation will be accessible on the "Events & Presentations" page of the "News & Events" section of Cascadian Therapeutics' website at www.cascadianrx.com.
About Cascadian Therapeutics
Cascadian Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer. Our lead product candidate, tucatinib, also known as ONT-380, is an orally active and selective small molecule HER2 inhibitor, which has been studied in approximately 200 patients to date. Preliminary results from two ongoing Phase 1b studies of tucatinib in combination showed promising systemic activity, a favorable safety profile and encouraging activity against brain metastases. Cascadian Therapeutics is also conducting a randomized, double-blind, placebo-controlled Phase 2 study called HER2CLIMB. The study is evaluating tucatinib versus placebo in combination with capecitabine and trastuzumab in late stage HER2+ breast cancer patients, with and without brain metastases, who have previously been treated with a taxane, trastuzumab, pertuzumab and T-DM1. This study is expected to enroll 180 patients across approximately 100 clinical sites in the U.S., Canada, and Western Europe. The Company is also developing a cell cycle inhibitor, Chk1, and plans to move the program forward through IND-enabling studies in 2017. For more information, visit www.cascadianrx.com.
Investor Contact: Julie Rathbun Rathbun Communications 206-769-9219 [email protected] Tricia Truehart The Trout Group 646-378-2953 [email protected] Media Contact: Amy Bonanno BMC Communications 646-513-3117 [email protected]
